RxDoctor Payments Data

Rahul Gupta, MD

Internal Medicine · Fairfield, CTNPI 1245421213

Payments from drug & device makers

$738in general payments, 2019–2025

Across 27 payments — averaging $27.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$168
  • Abbott$150
  • Novo Nordisk$125
  • Edwards Lifesciences$111
  • Otsuka America Pharmaceutical, Inc.$54
  • Exact Sciences$48
  • plus $82 from 5 others

What the payments were for

  • Food & beverage$738100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$738 in reported general payments places this provider in the 70th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$90,820
Medicare patients
387
Services billed
816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban421$191,526
JardianceEmpagliflozin126$87,717
XifaxanRifaximin39$51,920
XareltoRivaroxaban89$36,571
FarxigaDapagliflozin Propanediol46$27,826
JanuviaSitagliptin Phosphate34$27,387
CreonLipase/Protease/Amylase12$26,403
MyrbetriqMirabegron50$19,895
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$13,233
RybelsusSemaglutide11$12,270
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr28$12,037
OzempicSemaglutide11$11,402
Atorvastatin Calcium877$9,550
MultaqDronedarone Hcl18$8,894
EntrestoSacubitril/Valsartan18$8,408

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$191,526421 claims
AbbVieCreon, Linzess, Synthroid$168$38,01860 claims
Novo NordiskRybelsus, Ozempic$125$23,67222 claims
Astellas Pharma US IncMyrbetriq$14$19,89550 claims
Sumitomo Pharma America, Inc.Gemtesa$7$6,53711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Fairfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →